1 report

  • SCHNELL BIOPHARMA COMPLETES ISSUE OF EIGHTH UNSECURED BONDS DUE 2014 FOR US$14.5 MILLION
  • SCHNELL BIOPHARMA COMPLETES ISSUE OF NINTH UNSECURED BONDS DUE 2014 FOR US$8.8 MILLION

Its products portfolio includes antibiotics, infusions, containing amino acid, vitamin and hepatic protect infusions; gastrointestinal agents, comprising of digestives and antiulcerants.

  • Gastrointestinal Drug
  • South Korea
  • Corporate Finance
  • M&A
  • Biopharmaceuticals Inc.